FY26 Appendix 4E and Full Year Results
Filed with ASX · · 45 pages · English
Summary by 6ix AI
The company reported total revenue growth driven by strong sales in its Myriad product line, alongside a notable increase in normalized EBITDA. Looking ahead, Aroa has provided revenue guidance for the next fiscal year, anticipating further growth supported by strategic investments in sales and infrastructure. The filing includes a detailed financial report and an independent auditor's opinion confirming the accuracy of the financial statements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Aroa Biosurgery
- ARX FY26 Preliminary Results
- Symphony Randomised Control Trial Complete
- AROA Business Update Presentation
- AROA Business Update
- Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
Later from Aroa Biosurgery
- FY26 Full Year Results Presentation
- Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
- Symphony Significantly Improves DFU Healing
- Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery